The group's principal activities are marketing, selling and developing pharmaceutical products utilising its proprietary drug delivery technologies. Some of its products are permax a treatment for Parkinson's disease, zelapar an oral tablet uses a selective mao-b inhibitor and lax-101 which is to treat huntington's disease. It focuses on neurology and pain management, pharmaceutical development and marketing business, and drug delivery business in the United Kingdom, United States and Sweden.
